Question · asked by 1 review
Infliximab vs purine analogues: Loss of clinical response
- Population
- Participants with Crohn's disease in remission
- Intervention
- Infliximab
- Comparison
- purine analogues
- Outcome
- Loss of clinical response
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) The review found no eligible studies for this question. Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.